These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
873 related articles for article (PubMed ID: 18640458)
1. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Holmes C; Boche D; Wilkinson D; Yadegarfar G; Hopkins V; Bayer A; Jones RW; Bullock R; Love S; Neal JW; Zotova E; Nicoll JA Lancet; 2008 Jul; 372(9634):216-23. PubMed ID: 18640458 [TBL] [Abstract][Full Text] [Related]
2. Persistent neuropathological effects 14 years following amyloid-β immunization in Alzheimer's disease. Nicoll JAR; Buckland GR; Harrison CH; Page A; Harris S; Love S; Neal JW; Holmes C; Boche D Brain; 2019 Jul; 142(7):2113-2126. PubMed ID: 31157360 [TBL] [Abstract][Full Text] [Related]
3. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Boche D; Denham N; Holmes C; Nicoll JA Acta Neuropathol; 2010 Sep; 120(3):369-84. PubMed ID: 20632020 [TBL] [Abstract][Full Text] [Related]
4. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Winblad B; Andreasen N; Minthon L; Floesser A; Imbert G; Dumortier T; Maguire RP; Blennow K; Lundmark J; Staufenbiel M; Orgogozo JM; Graf A Lancet Neurol; 2012 Jul; 11(7):597-604. PubMed ID: 22677258 [TBL] [Abstract][Full Text] [Related]
5. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Boche D; Donald J; Love S; Harris S; Neal JW; Holmes C; Nicoll JA Acta Neuropathol; 2010 Jul; 120(1):13-20. PubMed ID: 20532897 [TBL] [Abstract][Full Text] [Related]
6. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056 [TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Vellas B; Black R; Thal LJ; Fox NC; Daniels M; McLennan G; Tompkins C; Leibman C; Pomfret M; Grundman M; Curr Alzheimer Res; 2009 Apr; 6(2):144-51. PubMed ID: 19355849 [TBL] [Abstract][Full Text] [Related]
8. Aβ43 in human Alzheimer's disease: effects of active Aβ42 immunization. Jäkel L; Boche D; Nicoll JAR; Verbeek MM Acta Neuropathol Commun; 2019 Sep; 7(1):141. PubMed ID: 31477180 [TBL] [Abstract][Full Text] [Related]
9. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Demattos RB; Lu J; Tang Y; Racke MM; Delong CA; Tzaferis JA; Hole JT; Forster BM; McDonnell PC; Liu F; Kinley RD; Jordan WH; Hutton ML Neuron; 2012 Dec; 76(5):908-20. PubMed ID: 23217740 [TBL] [Abstract][Full Text] [Related]
10. Microglial alterations in human Alzheimer's disease following Aβ42 immunization. Zotova E; Holmes C; Johnston D; Neal JW; Nicoll JA; Boche D Neuropathol Appl Neurobiol; 2011 Aug; 37(5):513-24. PubMed ID: 21166690 [TBL] [Abstract][Full Text] [Related]
11. [Current trend of immunotherapy for Alzheimer's disease]. Matsumoto SE; Tabira T Nihon Rinsho; 2011 Sep; 69(9):1628-32. PubMed ID: 21922765 [TBL] [Abstract][Full Text] [Related]